DOXYCYCLINE - doxycycline capsule Lupin Pharmaceuticals,Inc.


Doxycycline Capsules, USP Rx only

To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline capsules and other antibacterial drugs, doxycycline capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DESCRIPTION

Doxycycline is a broad-spectrum antibacterial synthetically derived from oxytetracycline. Doxycycline capsules USP, 50 mg, 75 mg, and 100 mg contain doxycycline monohydrate equivalent to 50 mg, 75 mg, and 100 mg of doxycycline for oral administration. The chemical designation of the light yellow to pale yellow powder is 2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,[4S-(4α , $4a\alpha$, 5α , $5a\alpha$, 6α , $12a\alpha$)]-,monohydrate.

Structural formula:



```
C_{22}H_{24}N_2O_8 \cdot H_2O M.W. = 462.45
```

Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.

Inert ingredients: colloidal silicon dioxide; magnesium stearate; microcrystalline cellulose; sodium starch glycolate; and a hard gelatin capsule which contains titanium dioxide, FD&C Red # 3, D&C Yellow # 10, gelatin, sodium lauryl sulfate, for the 50 mg strength; iron oxide black, iron oxide red, iron oxide yellow, titanium dioxide, gelatin, sodium lauryl sulfate for the 75 mg strength and iron oxide black, Iron Oxide Red, Iron Oxide Yellow, Titanium Dioxide, FD & C Red # 3, D&C Yellow # 10, gelatin, sodium lauryl sulfate for the 100 mg strength. The capsules are printed with edible ink containing shellac, titanium dioxide, black iron oxide, red iron oxide and potassium hydroxide for 50 mg, 75 mg and 100 mg strengths.

CLINICAL PHARMACOLOGY

Tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Doxycycline is virtually completely absorbed after oral administration.

Following a 200 mg dose of doxycycline monohydrate, 24 normal adult volunteers averaged the following serum concentration values:

Time (hr):	0.5	1.0	1.5	2.0	3.0	4.0	8.0	12.0	24.0	48.0	72.0
Conc.	1.02	2.26	2.67	3.01	3.16	3.03	2.03	1.62	0.95	0.37	0.15 (mcg/mL)

Average Observed Values Maximum Concentration Time of Maximum Concentration Elimination Rate Constant

3.61 mcg/mL (± 0.9 sd) 2.60 hr (± 1.10 sd) 0.049 per hr (± 0.030 sd) Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min). This percentage excretion may fall as low as 1-5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min). Studies have shown no significant difference in serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely impaired renal function.

Hemodialysis does not alter serum half-life.

Microbiology:

Mechanism of Action

Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. Cross resistance with other tetracyclines is common. Doxycycline has been shown to be active against most isolates of the following microorganisms, both *in vitro* and in clinical infections as described in the INDICATIONS AND USAGE section of the package insert.

Gram-Negative Bacteria Acinetobacter species Bartonella bacilliformis Brucella species Enterobacter aerogenes Escherichia coli Francisella tularensis Haemophilus ducreyi Haemophilus influenzae Klebsiella granulomatis Klebsiella species Neisseria gonorrhoeae Shigella species Vibrio cholerae Vibrio fetus Yersinia pestis **Gram-Positive Bacteria** Bacillus anthracis Streptococcus pneumoniae Anaerobes Clostridium species Fusobacterium fusiforme Propionibacterium acnes **Other Bacteria** Norcardiae and other aerobic Actinomyces species

Borrelia recurrentis

Chlamydophila psittaci

Chlamydia trachomatis

Mycoplasma pneumoniae

Rickettsiae

Treponema pallidum

Treponema pallidum subspecies pertenue

Ureaplasma urealyticum

Parasites

Balantidium coli

Entamoeba species

Plasmodium falciparum*

*Doxycycline has been found to be active against the asexual erythrocytic forms of *Plasmodium falciparum*, but not against the gametocytes of *P. falciparum*. The precise mechanism of action of the drug is not known.

Susceptibility Testing Methods

When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.

Dilution Techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method (broth and /or agar).^{1,2,4,6,7} The MIC values should be interpreted according to criteria provided in Table 1.

Diffusion Techniques

Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds.

The zone size should be determined using a standardized test method.^{1,3,4} This procedure uses paper disks impregnated with 30 mcg doxycycline to test the susceptibility of bacteria to doxycycline. The disk diffusion interpretive criteria are provided in Table 1.

Anaerobic Techniques

For anaerobic bacteria, the susceptibility to doxycycline can be determined by a standardized test method.5 The MIC values obtained should be interpreted according to the criteria provided in Table 1.

Bacteria*		al Inhibito			e Diam	eter	Agar D	ilution	(mcg
	Concentrat	ion (mcg	per mL)	(mm)		p	er mL)	_
	S	I	R	S	-	R	S	I	R
Acinetobacter spp.				≥13	10 to	≤9			
Doxycycline	≤4	8	≥16		12		-	-	-
Tetracycline	≤4	8	≥16	≥15	12 to 14	≤11	-	-	-
Anaerobes									
Tetracycline	-	-	-	-	-	-	≤4	8	≥16
Bacillus anthracis†									
Doxycycline	≤1	-	-	-	-	-	-	-	-
Tetracycline	≤1	-	-	-	-	-	-	-	-
Brucella species†									
Doxycycline	≤1	-	-	-	-	-	-	-	-
Tetracycline	≤1	-	-	-	-	-	-	-	-
Enterobacteriaceae									
Doxycycline	≤4	8	≥16	≥14	11 to 13	≤10	-	-	-
Tetracycline	≤4	8	≥16	≥15	12 to 14	≤11	-	-	-
<i>Franciscella tularensis†</i> Doxycycline	≤4	-	-	-	-	-	-	-	-
Tetracycline	≤4	-	-	-	-	-	-	-	-

Table 1: Susceptibility Test Interpretive Criteria for Doxycycline and Tetracycline

Haemophilus influenzae	≤2	4	≥8	≥29		≤25	-		
Tetracycline					28			-	-
<i>Mycoplasma pneumoniaet</i> Tetracycline	-	-	-		-	-	≤2	-	-
<i>Neisseria gonorrhoeae</i> ‡ Tetracycline				≥38		≤30			≥2
	-	-	-		31 to 37		≤0.25	0.5 to 1	
Norcardiae and other aerobic Actinomyces species†									
Doxycycline	≤1	2 to 4	≥8	-	-	-	-	-	-
Streptococcus pneumoniae									
Doxycycline	≤0.25	0.5	>1	>28	25 to 27	<24	-	-	-
Tetracycline	<1	2	>4	>28	25 to 27	<24	-	-	-
Vibrio cholerae									
Doxycycline	≤4	8	≥16	-	-	-	-	-	-
Tetracycline	≤4	8	≥16	-	-	-	-	-	-
Yersinia pestis									
Doxycycline	≤4	8	≥16	-	-	-	-	-	-
Tetracycline	≤4	8	≥16	-	-	-	-	-	-
Ureaplasma urealyticum									
Tetracycline	-	-	-	-	-	-	≤1	-	≥2

*Organisms susceptible to tetracycline are also considered susceptible to doxycycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline.

[†] The current absence of resistance isolates precludes defining any results other than "Susceptible". If isolates yielding MIC results other than susceptible, they should be submitted to a reference laboratory for further testing.

[‡] Gonococci with 30 mcg tetracycline disk zone diameters of < 19 mm usually indicate a plasmid-mediated tetracycline resistant *Neisseria gonorrhoeae* isolate. Resistance in these strains should be confirmed by a dilution test (MIC ≥ to 16 mcg/mL).

A report of Susceptible (S) indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the infection site necessary to inhibit growth of the pathogen. A report of *Intermediate* (I) indicates that the result should be considered equivocal, and, if the bacteria is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug product is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of *Resistant* (R) indicates that the pathogen is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.

Quality Control

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test.^{1,2,3,4,5,6,7} Standard doxycycline and tetracycline powders should provide the following range of MIC values noted in Table 2. For the diffusion technique using the 30 mcg doxycycline disk the criteria noted in **Table 2** should be achieved.

Table 2: Acceptable Quality Control Ranges for Susceptibility Testing for Doxycycline and Tetracycline

QC Strain	Minimal Inhibitory Concentration (mcg /mL)	Zone Diamete (mm)	rAgar Dilution (mcg/mL)
Enterococcus faecalis ATCC 29212			
Doxycycline	2 to 8	-	-
Tetracycline	8 to 32	-	-
Escherichia coli ATCC 25922			
Doxycycline	0.5 to 2	18 to 24	-
Tetracycline	0.5 to 2	18 to 25	-
Eggerthella lenta ATCC 43055			
Doxycycline	2 to 16	-	-
Haemophilus influenzae ATCC 49247			
Tetracycline	4 to 32	14 to 22	-
Neisseria gonorrhoeae ATCC 49226			
Tetracycline	-	30 to 42	0.25 to 1

Staphylococcus aureus ATCC 25923			
Doxycycline	-	23 to 29	-
Tetracycline	-	24 to 30	-
Staphylococcus aureus ATCC 29213			
Doxycycline	0.12 to 0.5	-	-
Tetracycline	0.12 to 1	-	-
Streptococcus pneumoniae ATCC 49619			
Doxycycline	0.015 to 0.12	25 to 34	-
Tetracycline	0.06 to 0.5	27 to 31	-
Bacteroides fragilis ATCC 25285			
Tetracycline	-	-	0.125 to 0.5
Bacteroides thetaiotaomicron ATCC 29741			
Doxycycline	2 to 8	-	-
Tetracycline	-	-	8 to 32
Mycoplasma pneumoniae ATCC 29342			
Tetracycline	0.06 to 0.5	-	0.06 to 0.5
Ureaplasma urealyticum ATCC 33175			
Tetracycline	-	-	≥8

INDICATIONS AND USAGE

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Doxycycline is indicated for the treatment of the following infections:

Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by *Rickettsiae*.

Respiratory tract infections caused by Mycoplasma pneumoniae

Lymphogranuloma venereum caused by Chlamydia trachomatis

Psittacosis (ornithosis) caused by Chlamydophila psittaci

Trachoma caused by *Chlamydia trachomatis*, although the infectious agent is not always eliminated as judged by immunofluorescence

Inclusion conjunctivitis caused by Chlamydia trachomatis

Uncomplicated urethral, endocervical or rectal infections in adults caused by *Chlamydia trachomatis*

Nongonococcal urethritis caused by Ureaplasma urealyticum

Relapsing fever due to Borrelia recurrentis.

Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms:

Chancroid caused by Haemophilus ducreyi

Plague due to Yersinia pestis.

Tularemia due to Francisella tularensis

Cholera caused by Vibrio cholerae

Campylobacter fetus infections caused by Campylobacter fetus

Brucellosis due to Brucella species (in conjunction with streptomycin)

Bartonellosis due to Bartonella bacilliformis

Granuloma inguinale caused by Calymmatobacterium granulomatis.

Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.

Doxycycline is indicated for treatment of infections caused by the following gramnegative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:

Escherichia coli

Enterobacter aerogenes

Shigella species

Acinetobacter species

Respiratory tract infections caused by Haemophilus influenzae

Respiratory tract and urinary tract infections caused by Klebsiella species.

Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:

Upper respiratory infections caused by Streptococcus pneumoniae

Anthrax due to *Bacillus anthracis*, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized *Bacillus anthracis*.

When penicillin is contraindicated, doxycycline is an alternative in the treatment of the following infections:

Uncomplicated gonorrhea caused by Neisseria gonorrhoeae

Syphilis caused by Treponema pallidum

Yaws caused by Treponema pertenue

Listeriosis due to Listeria monocytogenes

Vincent's infection caused by Fusobacterium fusiforme

Actinomycosis caused by Actinomyces israelii

Infections caused by *Clostridium species*.

In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides.

In severe acne, doxycycline may be useful adjunctive therapy.

CONTRAINDICATIONS

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

WARNINGS

THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP, EXCEPT FOR ANTHRAX, INCLUDING INHALATIONAL ANTHRAX (POST-EXPOSURE), UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline capsules, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.

Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.

The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

PRECAUTIONS

General:

As with other antibacterial preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, the antibiotic should be discontinued and appropriate therapy instituted.

Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including doxycycline. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and doxycyline should be avoided because isotretinoin is also known to cause pseudotumor cerebri.

Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.

Incision and drainage or other surgical procedures should be performed in conjunction with antibacterial therapy when indicated.

Prescribing doxycycline capsules in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for Patients:

All patients taking doxycycline should be advised:

-to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if phototoxicity (e.g., skin eruptions, etc.) occurs. Sunscreen or sunblock should be considered. (See WARNINGS.)

-to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration. (See ADVERSE REACTIONS.)

-that the absorption of tetracyclines is reduced when taken with foods, especially those which contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk. (See Drug Interactions.)

-that the absorption of tetracyclines is reduced when taking bismuth subsalicylate. (See Drug Interactions.)

-not to use outdated or poorly stored doxycycline.

-that the use of doxycycline might increase the incidence of vaginal candidiasis.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Patients should be counseled that antibacterial drugs including doxycycline capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When doxycycline capsules are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by doxycycline capsules or other antibacterial drugs in the future.

Laboratory Tests:

In venereal disease when coexistent syphilis is suspected, a dark-field examination should be done before treatment is started and the blood serology repeated monthly for at least four months.

In long-term therapy, periodic laboratory evaluations of organ systems, including hematopoietic, renal, and hepatic studies should be performed.

Drug Interactions:

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.

Concurrent use of tetracycline may render oral contraceptives less effective.

Drug/Laboratory Test Interactions:

False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Long-term studies in animals to evaluate the carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with related antibacterial, oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in *in vitro* mammalian cell assays have been reported for related antibacterial (tetracycline, oxytetracycline). Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied.

Pregnancy:

Teratogenic Effects.

Pregnancy Category D:

There are no adequate and well-controlled studies on the use of doxycycline in pregnant short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for treatment of anthrax exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS - the Teratogen Information System - concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk.⁸

A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. (Sixty-three [0.19%] of the controls and 56 [0.30%] of the cases were treated with doxycycline.) This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (i.e., in the second and third months of gestation) with the exception of a marginal relationship with neural tube defect based on only two exposed cases.⁹

A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age.¹⁰

Labor and Delivery:

The effect of tetracyclines on labor and delivery is unknown

Nursing Mothers:

Tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines, including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarily contraindicated; however, the effects of prolonged exposure to doxycycline in breast milk are unknown.¹¹ Because of the potential for adverse reactions in nursing infants from doxycycline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (See WARNINGS.)

Pediatric Use:

See WARNINGS and DOSAGE AND ADMINISTRATION sections.

ADVERSE REACTIONS

Due to oral doxycycline's virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines.

Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (See DOSAGE AND ADMINISTRATION.)

Skin: Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme have been reported. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (See WARNINGS.)

Renal Toxicity: Rise in BUN has been reported and is apparently dose related. (See WARNINGS.)

Hypersensitivity Reactions: Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus.

Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported with tetracyclines.

Other: Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines. (See PRECAUTIONS-General.)

When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. No abnormalities of thyroid function are known to occur.

OVERDOSAGE

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life, and it would not be of benefit in treating cases of overdosage.

DOSAGE AND ADMINISTRATION

THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.

Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours or 50 mg every 6 hours) followed by a maintenance dose of 100 mg/day. The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. In the management of more severe infections

(particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.

For pediatric patients above eight years of age: The recommended dosage schedule for pediatric patients weighing 100 pounds or less is 2 mg/lb of body weight divided into two doses on the first day of treatment, followed by 1 mg/lb of body weight given as a single daily dose or divided into two doses, on subsequent days. For more severe infections up to 2 mg/lb of body weight may be used. For pediatric patients over 100 pounds the usual adult dose should be used.

Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice a day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose.

Acute epididymo-orchitis caused by *N. gonorrhoeae:* 100 mg, by mouth, twice a day for at least 10 days.

Primary and secondary syphilis: 300 mg a day in divided doses for at least 10 days.

Uncomplicated urethral, endocervical, or rectal infection in adults caused by *Chlamydia trachomatis:* 100 mg, by mouth, twice a day for at least 7 days.

Nongonococcal urethritis caused by *C. trachomatis* and *U. urealyticum:* 100 mg, by mouth, twice a day for at least 7 days.

Acute epididymo-orchitis caused by *C. trachomatis:* 100 mg, by mouth, twice a day for at least 10 days.

Inhalational anthrax (post-exposure): ADULTS: 100 mg of doxycycline, by mouth, twice a day for 60 days. CHILDREN: weighing less than 100 pounds (45 kg); 1 mg/lb (2.2 mg/kg) of body weight, by mouth, twice a day for 60 days. Children weighing 100 pounds or more should receive the adult dose.

When used in streptococcal infections, therapy should be continued for 10 days.

Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (See ADVERSE REACTIONS.) If gastric irritation occurs, doxycycline may be given with food. Ingestion of a high fat meal has been shown to delay the time to peak plasma concentrations by an average of one hour and 20 minutes. However, in the same study, food enhanced the average peak concentration by 7.5% and the area under the curve by 5.7%.

HOW SUPPLIED

Doxycycline Capsules, USP 50 mg have a yellow opaque cap and a white opaque body. The capsules are imprinted "NL 790" with white ink on the cap and "50 mg" with brown ink on the body, filled with yellow to beige powder. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline.

Doxycycline Capsules, USP 50 mg is available in:

Bottles of 50 capsules	NDC 43386-790-11
Bottles of 100 capsules	NDC 43386-790-01
Bottles of 1000 capsules	NDC 43386-790-10

Doxycycline Capsules, USP 75 mg have a brown opaque cap and a white opaque body. The capsules are imprinted "NL 791" with white ink on the cap and "75 mg" with brown ink on the body, filled with yellow to beige powder. Each capsule contains doxycycline monohydrate equivalent to 75 mg doxycycline.

Doxycycline Capsules, USP 75 mg is available in:

Bottles of 50 capsulesNDC 43386-791-11

Bottles of 100 capsulesNDC 43386-791-01

Bottles of 1000 capsulesNDC 43386-791-10

Doxycycline Capsules, USP 100 mg have a brown opaque cap and a yellow opaque body. The capsules are imprinted "NL 792" with white ink on the cap and "100 mg" with brown ink on the body, filled with yellow to beige powder. Each capsule contains doxycycline monohydrate equivalent to 100 mg doxycycline.

Doxycycline Capsules, USP 100 mg is available in:

Bottles of 50 capsules	NDC 43386-792-11
Bottles of 250 capsules	NDC 43386-792-02
Bottles of 1000 capsules	NDC 43386-792-10

STORE AT 20° to 25°C (68° to 77°F). [SEE USP CONTROLLED ROOM TEMPERATURE.]

DISPENSE IN A TIGHT, LIGHT-RESISTANT CONTAINER AS DEFINED IN THE USP/NF.

PROTECT FROM LIGHT.

ANIMAL PHARMACOLOGY AND OR TOXICOLOGY

Hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO_4 , and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO_4 , and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.

Minocycline, tetracycline PO₄, methacycline, doxycycline, tetracycline base, oxytetracycline HCl and tetracycline HCl were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet.

Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline), in chickens (chlortetracycline) and in rats and mice (oxytetracycline). Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline.

REFERENCES

- Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing; Twentyfifth Informational Supplement*, CLSI document M100-S25. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
- Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - 10th ed. CLSI document M07- A10. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
- 3. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard 11th ed.* CLSI document M02-A12. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
- Clinical and Laboratory Standards Institute. *Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline—Second Edition*. CLSI document M45-A2. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2010.
- Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - Eighth Edition. CLSI document M11-A8. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087 USA, 2012.
- Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard—Second Edition. CLSI document M24-A2. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA. 2011.
- Clinical and Laboratory Standards Institute. *Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline.* CLSI document M43-A. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA. 2011.

Rx only

Novel Laboratories, Inc. 400 Campus Drive

Somerset, NJ 08873

Manufactured for:

GAVIS Pharmaceuticals, LLC

Somerset, NJ 08873 PI7920000202 Revised: 10/2015

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Doxycycline Capsules, USP 50 mg 1000 count



Doxycycline Capsules, USP 75 mg 100 count



Doxycycline Capsules, USP 100 mg

50 count

DOXYCYCLINE doxycycline capsule



DOXYCYCLINE (UMI: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE MAHYDROUS 50 mg Inactive Ingredients Strength								
Route of Administration ORAL Active Ingredient/Active Molety Basis of Strength Strength DOVECVCLINE (INIE: N1200001130) (DOVECTCLINE ANHYDROUS - DOVECVCLINE SUPPORT Inactive Ingredients Ingredient Name Strength Stuccon DIOXIDE (UNIE: TYPE A POTATO (UNIE: 5856)G2A2) Tranuou DIOXIDE (UNIE: STRENUP) Strength Solution Straket (UNIE: 10097M6800) Cellulose, MicroPortVacLINE (UNIE: 1578901) Strength Solution Straket (UNIE: 10097M6800) Cellulose, MicroPortVacLINE (UNIE: 15789020) Strength Solution Straket (UNIE: 15789020) Strength Strength Solution Straket (UNIE: 15789020) Strength Strength Solution Prozent (UNIE: 15789020) Strength Strength Solution Proceed (UNIE: 15789020) Strength Strength Solution Proceed (UNIE: 15799020) Strength Strength Solution Proceed (UNIE: 15799020) Strength Strength Product Characteristics Strength Strength Color YELLOV (VORaque Cap)., WHTE (Opaque Body) Store No Store Shape CAPSULE Strength Marketing End NCC43386-790: Io0 in 1 BOTHE: Type 0: Not a Combination 0708/2015 0708/2015 1 NCC43386-790: Io10 In 1 BOTHE: Type 0: No	Product Inf	ormation						
Active Ingredient/Active Moiety Ingredient Name DOXYCYCLINE (INE 122000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE (INE 122000U130) (DOXYCYCLINE ANHYDROUS - DOXYCRUE UNE 3348955862) Inactive Ingredients Ingredient Name Inactive Ingredients Ingredient Name Strength Strengt Strength Strength Strengt Strengt Strength Strengt Strengt Strength Strengt Strength Strengt Str	Product Type		HUMAN PRESCRIPTION DRUG	ltem C	ode (Source)	NDC:4	3386-790	
Ingredient Name Basis of Strength Strength DDXYCYCLLIME (UNII: M12000U13:0) (DDXYCYCLIME ANHYDROUS - DDXYCYCLIME (MIII: M12000U13:0) (DDXYCYCLIME ANHYDROUS - DDXYCYCLIME (MIII: M12000U13:0) (DDXYCYCLIME ANHYDROUS - DDXYCYCLIME (MIII: M12000U13:0) (DDXYCYCLIME (MIII: M12000U13:0) (DXXCYCLIME (MIIII: M12000U13:0) (DXXCYCLIME (MIII: M12000U13:0) (DXXXYCHIA (MIII: M111: M1111: M111: M1111: M111: M111: M1111: M111: M1111: M111: M111: M111:	Route of Adm	ninistration	ORAL					
Ingredient Name Basis of Strength Strength DDXYCYCLLIME (UNII: M12000U13:0) (DDXYCYCLIME ANHYDROUS - DDXYCYCLIME (MIII: M12000U13:0) (DDXYCYCLIME ANHYDROUS - DDXYCYCLIME (MIII: M12000U13:0) (DDXYCYCLIME ANHYDROUS - DDXYCYCLIME (MIII: M12000U13:0) (DDXYCYCLIME (MIII: M12000U13:0) (DXXCYCLIME (MIIII: M12000U13:0) (DXXCYCLIME (MIII: M12000U13:0) (DXXXYCHIA (MIII: M111: M1111: M111: M1111: M111: M111: M1111: M111: M1111: M111: M111: M111:								
Ingredient Name Basis of Strength Strength DDXYCYCLLIME (UNII: M12000U13:0) (DDXYCYCLIME ANHYDROUS - DDXYCYCLIME (MIII: M12000U13:0) (DDXYCYCLIME ANHYDROUS - DDXYCYCLIME (MIII: M12000U13:0) (DDXYCYCLIME ANHYDROUS - DDXYCYCLIME (MIII: M12000U13:0) (DDXYCYCLIME (MIII: M12000U13:0) (DXXCYCLIME (MIIII: M12000U13:0) (DXXCYCLIME (MIII: M12000U13:0) (DXXXYCHIA (MIII: M111: M1111: M111: M1111: M111: M111: M1111: M111: M1111: M111: M111: M111:	Active Ingre	edient/Active	Moiety					
UNIL:3348955867) In the image of the image o			•		Basis of S	trength	Strength	
Inactive Ingredients Ingredient Name Strength SILCON DIOXIDE (UMI: ETT7263904) MAGNESIUM STEARATE (UMI: 70037M6130) CELLUOSE, MICHOCRYSTALLINE (UMI: 0218320610) CELLUOSE, MICHOCRYSTALLINE (UMI: 0218320610) CELLUOSE, MICHOCRYSTALLINE (UMI: 0218320610) CELLUOSE, MICHOCRYSTALLINE (UMI: 0218320610) DEC TED IOX (UMI: 25180720) DEC TED IOX (UMI: 25180720) DEC TED IOX (UMI: 25180720) DEC TELIOW KO, 10 (UMI: 3518050503G) GELATIN (UMI: 268078710) DEC TELIOW KO, 10 (UMI: 3518050503G) GELATIN (UMI: 268078710) SECLE CONDE (UMI: X009736675) POTASSIUM HYDROXIDE (UMI: X00973675) POTASSIUM HYDROXIDE (UMI: X00973675) POTASSIUM HYDROXIDE (UMI: X00974640000 01/31/2040 POROUCE 1000 In 1 BOTTLE: Type 0: Not a Combination 01/31/2040 Product Product 100 ID 1 BOTTLE: Type 0: Not a Combination 01/31/2040 MARKETING INFORMATION Marketing Information Marketing Application Number or Monograph Marketing Start Marketing End Date Product Information Product Information Product Information Product Information ORAL Product Information Product INFORMANIAN PRESCRIPTION DRUG TER Code (Source) NDC:43386-791 Rute of Administration ORAL Active Ingredient/Active Molety Ingredient Name Product Information) (DOXYCYCLINE ANHYDROUS -				50 mg	
Ingredient Name Strength SILICON DIOXIDE (UNII: ET7/26X8U4) MAGNESIUM STEARATE (UNII: 2097M6130) Improve Name CELLULOSE, MICROCRYSTALLINE (UNII: 2017320511) Solution Strack of Action Line (UNII: 2017320512) Improve Name DOC YELLOW NO. 10 (UNII: 257K9V2)P) Face Rep No. 3 (UNII: MA2145L00Y) Social Strangth Improve Name DOC YELLOW NO. 10 (UNII: 258G05121)) Solution Strack (UNII: 268G05121)) Improve Name Improve Name Shee C VELLOW NO. 10 (UNII: 258G05127) Ferenco XOLE Rep (UNII: 20078G673) Imprint Code Imprint Code Product Characteristics Color YELLOW (Opaque Cap), WHTE (Opaque Body) Score no score Shape CAPSULE Jamm Imprint Code NL790;50mg Flavor Imprint Code NL790;50mg Date Packaging # MocA3386-790- 100 in 1 BOTTLE; Type 0: Not a Combination Product Bottle; Type 0: Not	01011:5546955602	2)			ANTIDROUS		-	
Ingredient Name Strength SILICON DIOXIDE (UNII: ET7/26X8U4) MAGNESIUM STEARATE (UNII: 2097M6130) Improve Name CELLULOSE, MICROCRYSTALLINE (UNII: 2017320511) Solution Strack of Action Line (UNII: 2017320512) Improve Name DOC YELLOW NO. 10 (UNII: 257K9V2)P) Face Rep No. 3 (UNII: MA2145L00Y) Social Strangth Improve Name DOC YELLOW NO. 10 (UNII: 258G05121)) Solution Strack (UNII: 268G05121)) Improve Name Improve Name Shee C VELLOW NO. 10 (UNII: 258G05127) Ferenco XOLE Rep (UNII: 20078G673) Imprint Code Imprint Code Product Characteristics Color YELLOW (Opaque Cap), WHTE (Opaque Body) Score no score Shape CAPSULE Jamm Imprint Code NL790;50mg Flavor Imprint Code NL790;50mg Date Packaging # MocA3386-790- 100 in 1 BOTTLE; Type 0: Not a Combination Product Bottle; Type 0: Not								
SILICON DIOXIDE (UNII: ETJ7ZEXBUA) MAGNESIUM STRAATE (UNII: 70097M630) CELULUOSE, MICROCRYSTALINE (UNII: 00918320510) SODUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856j3G2A2) TTANIUM DIOX0E (UNII: 1978/215LOQY) PGC RED NO. 3 (UNII: PN2TH5LOQY) DGC YELLOW NO. 10 (UNII: 355W5U503G) GELTMI (UNII: 26860N327) SODUM LAURYL SULPATE (UNII: 358W5U503G) GELTMI (UNII: 26860N327) SPELLAC (UNII: 46N1078710) FERROSOFEREC COXDE (UNII: 1009F3G675) POTASSIUM HYDROXIDE (UNII: 1009F3G675)	Inactive Ing	redients	In a weak out Now a				• · · · · · • • • • • •	
MAGNESIUM STEARATE (UNII: 70097M6(30) Image: Calculoss, MICROCKYSTALLNE (UNII: 385(6)362A2) Image: Calculoss, MICROCKYSTALLNE (UNII: 385(6)362A2) TTTANUM DIOXDE (UNII: 15FX9V2P) Image: Calculoss, MICROCKYSTALLNE (UNII: 385(6)362A2) Image: Calculoss, MICROCKYSTALLNE (UNII: 385(6)362A2) FD6C RED NO. 3 (UNII: PN22)FILOOY) Doc YelLOW NO. 10 (UNII: 35K0503G) Image: Calculoss, MICROCKYSTALLNE (UNII: 386(6)3141)) Stollum LAIRY, SUFATE (UNII: 386(6)3141) Stoce No. 3 (UNII: PN22)FILOOY) Image: Calculoss, MICROCKYSTAL Stollum LAIRY, SUFATE (UNII: 386(6)3141) Stoce No. 3 (UNII: PN22)FILOOY) Image: Calculoss, MICROCKYSTALLNE (UNII: 386(6)3141) Stollum LAIRY, SUFATE (UNII: 386(6)3141) Stoce No. 3 (UNII: PN22)FILOSS No score Poduct Characteristics Score No score No score Color YELLOW (Opaque Cap), WHTE (Opaque Body) Score No score No score Flavor Size No score No score No score Flavor Care (UNII: 167000000000000000000000000000000000000			-			5	trength	
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNIE S856)3G2A2) TITANUM DIOXNDE (UNIE : 15749020P) FOC CRE NO. 3 (UNIE : 157450027) DEC YELLOW NO. 10 (UNIE: 35576510070000000000000000000000000000000		· •						
TTTANIUM DIOXIDE (UNII: 15FIX9V2)P) FPGC RED NO.3 (UNII: PNZZHSLOGY) DEC YELLOW NO.10 (UNII: PNZZHSLOGY) SODUM LAURYL SULFATE (UNII: 368GB5141)) SIELLAC (UNII: 46NL07810) FERROSOFERRIC OXIDE (UNII: MOM87F357) FERRIC OXIDE RED (UNII: 1K09F3G675) POTASSIUM HYDROXIDE (UNII: WZH3C48M4T) Product Characteristics Color YELLOW (Opaque Cap), WHTE (Opaque Body) Score no score Shape CAPSULE UNII: WZH3C48M4T) Product Characteristics Color YELLOW (Opaque Cap), WHTE (Opaque Body) Score no score Shape CAPSULE UNII: MOM PROXIDE (UNII: WZH3C48M4T) Product Characteristics Color YELLOW (Opaque Cap), WHTE (Opaque Body) Score no score Shape CAPSULE UNII: Type Or Not a Combination 07/08/2015 Product Product Marketing Start Marketing Start Date NU.790;50mg Marketing Information Marketing Information Marketing Information Marketing Application Number or Monograph Marketing Start Date NDOXYCYCLINE ANDA ANDA20446 07/08/2015 DOXYCYCLINE ANDA ANDA20446 07/08/2015 Core NUE VIENDE VIENTE: Type 0: Not a Combination 01/31/2040 ANDA ANDA20446 07/08/2015 COXYCYCLINE ANDA ANDA20446 07/08/2015 COXYCYCLINE ANDA ANDA20446 07/08/2015 COXYCYCLINE Composition 0RAL Citation ORAL Citation ORA Citation ORA Citation O	CELLULOSE, MI	ICROCRYSTALLIN	E (UNII: OP1R32D61U)					
FD6C RED NO. 3 (UNII: PN2Z HSLOOY) Image: Stress (UNII: Stress (UNIII: Stress (UNIII: Stress (UNII: Stress (UNIIII: STRESS (2)				
bbC YELLOW NO. 10 (UNII: 355W5USQ3G) GELATIN UNII: 26860/327() SOUIM LAUKY SULFATE (UNII: 368G85141)) SHELLAC (UNII: 46N107B710) FERROSOFERRUC OXDE (UNII: XM0M87F357) FERROSOFERRUC OXDE (UNII: WZH3C48M4T) Product Characteristics Color YELLOW (Opaque Cap), WHITE (Opaque Body) Score no score Size 18mm Flavor CAPSULE Flavor CAPSULE Flavor CAPSULE Packaging # tem Code Package Description 1 NC:43386-790- 10 0 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 1 NDC:43386-790- 10 0 in 1 BOTTLE; Type 0: Not a Combination Product NDC:43386-790- 10 0 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 10 0 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 10 0 in 1 BOTTLE; Type 0: Not a Combination Marketing Information Marketing Information Marketing Application Number or Monograph Marketing Start Marketing End Date Product Information Product Type HUMAN PRESCRIPTION DRUG Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE NDC:43386-791- ND			• •					
GELATIN (UNII: 2686QN327L) SODUM LAURYL SULFATE (UNII: 368GB5141)) SODUM LAURYL SULFATE (UNII: 368GB5141)) FERROSOFERRIC OXIDE (UNII: 1009F36675) FERROSOFERRIC OXIDE (UNII: WZH3C48M4T) no score Product Characteristics size Color YELLOW (Opaque Cap), WHTE (Opaque Body) Score no score Shape CAPSULE Size 18mm Flavor Imprint Code NL790;50mg Packaging Imprint Code NL790;50mg # tem Code Package Description 07/08/2015 NOC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 07/08/2015 NOC:43386-790- 50 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 1 NDC:43386-790- 50 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 2 10 ID Forduct Type 0: Not a Combination 01/31/2040 3 NDC:43386-790- Solu in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 4 ID ANIDA204446 07/08/2015 ID DOXYCYCLINE AnIDA204446 07/08/2015 ID Froduct Information Froduct Type HUMAN PRESCRIPTION DRU								
SHELLAC (UNII: 46N107B710) FERROSOFERRIC OXIDE (UNII: XMOM37F337) FERROSOFERRIC OXIDE (UNII: XMOM37F337) POTASSIUM HYDROXIDE (UNII: WZH3C48M4T) Product Characteristics Color YELLOW (Opaque Cap), WHITE (Opaque Body) Score no score Shape CAPSULE Size 18mm Flavor Contains Packaging # Item Code Package Description Marketing Start Date ML790;50mg Contains Product 1 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 Marketing Information Marketing Application Number or Monograph Marketing Start Date NDC CA3386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 Product Marketing Capsule Product Information Product Information 0RAL NDC:43386-791 Route of Administration 0RAL NDC:43386-791 NDC:43386-79		•	665(56)					
FERROSOFERRIC OXIDE (UNII: XMOM37F357) FERRIC OXIDE RED (UNII: XMOM37F357) FERRIC OXIDE RED (UNII: XMOM37F357) FERRIC OXIDE RED (UNII: XMOM37F357) POTASSIUM HYDROXIDE (UNII: WZ H3C48M4T) Score no score Size 18mm Imprint Code N1790;50mg Packagging # tem Code Package Description Marketing Start Date Marketing Start Date 1 NC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination O1/31/2040 01/31/2040 Imprint Code Imprint	•		368GB5141J)					
FERRIC OXIDE RED (UNII: 1K09F3G675) Product Characteristics Score no score Score no score Score no score Score no score Imprint Code NL790;50mg Packaging # tem Code Package Description Marketing Start Marketing End Date 1 NCC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 01/08/2015 01/31/2040 01/31/2040 2 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 01/31/2040 01/31/2040 Marketing Information Marketing Start Marketing End Date Date MDA ANDA204446 07/08/2015 Marketing Start Marketing End Date DOXYCYCLINE datageory Application Number or Monograph Marketing Start Marketing End Date datageory ANDA204446 07/08/2015 NDC:43386-791 Route of Administration ORAL <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
POTASSIUM HYDROXIDE (UNII: WZ.H3C48M4T) Product Characteristics Color YELLOW (Opaque Cap), WHITE (Opaque Body) Score no score Shape CAPSULE IBmm Imprint Code NL790;50mg Contains Packaging # Item Code Package Description 07/08/2015 Product NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination Product Direction 07/08/2015 NC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination Product NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: NOT a Combination NDC:43386-790- 1000 in 1 BOTTLE; Type 0: NOT a Combination 01/31/2040 NDC:43386-790- 1000 in 1 BOTTLE; Type 0: NOT a Combination 01/31/2040 NDC:43386-790- 1000 ID (DOXCYCLINE (UNI: NDC:43386-791 NDC:43386-791 NDC:43386-791- 1000 ID (DOXCYCLINE ANHYDROUS - DOXYCYCLINE 100000130) (DOXCYCLINE 10000000000 - DOXCYCLINE 10000000000 - DOXCYCLINE 1000000000 - DOXCYCLINE 10000000000 - DOXCYCLINE 10000000000 - DOXCYCLINE 10000000000 - DOXCYCLINE 1000000000000000000000000000000000000								
Product Characteristics Color YELLOW (Opaque Cap), WHITE (Opaque Body) Score no score Shape CAPSULE Size 18mm Flavor Imprint Code NL790;50mg Ontains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 01(31/2040 01/31/2040 1 2 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination 10 01/31/2040 1 Marketing Information Marketing Application Number or Monograph Product Marketing Start Date Marketing End Date Marketing Start Category Application Number or Monograph Category Marketing Start Date Marketing End Date Product Information 07/08/2015 Product Information Product Type HUMAN PRESCRIPTION DRUG Marketing Start Date Marketing Fard Date Product Information Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code		•						
Color YELLOW (Opaque Cap), WHITE (Opaque Body) Score no score Shape CAPSULE Size 18mm Flavor Imprint Code NL790;50mg Contains Marketing Start Marketing Start Marketing End Date 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/08/2015 Marketing End 1 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 Imprint Code 2 NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 Imprint Code Imprint Code 3 NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 01/31/2040 Imprint Code Imprint Code Marketing Information Citation Number or Monograph Citation Start Date Marketing End Date Date ANDA ANDA204446 07/08/2015 Imprint Code Imprint Code Imprint Code Product Thformation Imprint Citation Number or Monograph Citation Start Date Marketing End Date Imprint Code Impredient Add Imprint Code	FOTASSIONIT		2113(401141)					
Color YELLOW (Opaque Cap), WHITE (Opaque Body) Score no score Shape CAPSULE Size 18mm Flavor Imprint Code NL790;50mg Contains Marketing Start Marketing Start Marketing End Date 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/08/2015 Marketing End 1 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 Imprint Code 2 NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 Imprint Code Imprint Code 3 NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 01/31/2040 Imprint Code Imprint Code Marketing Information Citation Number or Monograph Citation Start Date Marketing End Date Date ANDA ANDA204446 07/08/2015 Imprint Code Imprint Code Imprint Code Product Thformation Imprint Citation Number or Monograph Citation Start Date Marketing End Date Imprint Code Impredient Add Imprint Code								
Shape CAPSULE Size 18mm Flavor Imprint Code NL790;50mg Contains Packaging Imprint Code NL790;50mg Packaging Marketing Start Marketing End Date Date 1 NDC:43386-790- 10 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/08/2015 Imprint Code Imprint Code 2 NDC:43386-790- 11 100 in 1 BOTTLE; Type 0: Not a Combination 11 01/31/2040 Imprint Code Imprint Code MC:43386-790- 11 1000 in 1 BOTTLE; Type 0: Not a Combination 11 01/31/2040 Imprint Code Imprint Code Imprint Code Marketing Information Marketing Citation Number or Monograph Citation Marketing Start Date Marketing End Date DOXYCYCLINE doxycycline capsule HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL Basis of Strength Strength Ingredient Name Basis of Strength Strength DoxyCYCLINE Ingredient Name Basis of Strength Strength		aracteristics						
Imprint Code NL790;50mg Particle Contains Imprint Code NL790;50mg Particle Code Particle Code NL790;50mg Particle Code Narketing Start Marketing Start Marketing End Date Application Number or Monograph Citation Marketing Start Marketing End Date Application Number or Monograph Citation Marketing Start Marketing End Date Application Number or Monograph Citation Marketing Start Marketing End Date Application Number or Monograph Citation Marketing Start Marketing End Date Application Number or Monograph Marketing Start Marketing Start <th colspa<="" td=""><td></td><td></td><td>Cap) , WHITE (Opaque Body)</td><td></td><td></td><td></td><td></td></th>	<td></td> <td></td> <td>Cap) , WHITE (Opaque Body)</td> <td></td> <td></td> <td></td> <td></td>			Cap) , WHITE (Opaque Body)				
Contains Marketing Start Marketing End Date # Item Code Package Description Marketing Start Marketing End Date 1 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 Image: Code Code Code Code Code Code Code Code		CAPSULE						
Name of the second state of the second sta					Imprint Code	INL/9	10;50mg	
# Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:43386-790- 01 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/08/2015 01/31/2040 2 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 01/31/2040 3 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 01/31/2040 Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA ANDA ANDA204446 07/08/2015 Marketing End Date Product Information Product Information Product Information Muman Prescription Drug Route of Administration ORAL Marketing Start Drug And A ANDA204446 Product Information Product Information Product Information Route of Administration ORA Ingredient/Active Moiety Basis of Strength Strengt DOXYCYCLINE (UNII: N120000130) (DOXYCYCLINE ANYDROUS -	contains							
# Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:43386-790- 01 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/08/2015 01/31/2040 2 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 01/31/2040 3 NDC:43386-790- 100 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 01/31/2040 Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA ANDA ANDA204446 07/08/2015 Marketing End Date Product Information Product Information Product Information Muman Prescription Drug Route of Administration ORAL Marketing Start Drug And A ANDA204446 Product Information Product Information Product Information Route of Administration ORA Ingredient/Active Moiety Basis of Strength Strengt DOXYCYCLINE (UNII: N120000130) (DOXYCYCLINE ANYDROUS -								
Item Code Package Description Date Date 1 NDC:43386-790- 01 100 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 01/31/2040 2 NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 01/31/2040 3 NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 01/31/2040 Marketing Information Marketing Category Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204446 07/08/2015 07/08/2015 07/08/2015 Product Information Product Information Product Information Product Information MUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Product Information P	Packaging							
1 NDC:43386-790- 01 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/08/2015 2 NDC:43386-790- 10 50 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 3 NDC:43386-790- 10 1000 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 Marketing Information Marketing Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204446 07/08/2015 Marketing Start Date Marketing Start Date Marketing End Date Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - Basis of Strength Strength	# Item Cod	e Pa	ckage Description	Mark				
01 Product Product 01/31/2040 2 NDC:43386-790- 10 50 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 3 NDC:43386-790- 10 1000 in 1 BOTTLE; Type 0: Not a Combination Product 01/31/2040 Marketing Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204446 07/08/2015 07/08/2015 Product Information Product Information Product Information Product Information Product Information Product Information Product Type HUMAN PRESCRIPTION DRUG Route of Administration ORAL Active Ingredient/Active Moiety Basis of Strength Strengt DXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS -			LE; Type 0: Not a Combination	07/08/20			ute	
2 11 Product 01/31/2040 01/31/2040 3 NDC:43386-790- 1000 in 1 BOTTLE; Type 0: Not a Combination 01/31/2040 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date ANDA ANDA204446 07/08/2015 Marketing End Date DOXYCYCLINE doxycycline capsule Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Active Ingredient/Active Moiety Active Ingredient/Active Moiety Basis of Strength DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS -			F. Tura O. Nata Combination	07/00/20	15			
10 Product 01/31/2040 Marketing Information Application Number or Monograph Citation Marketing Start Date ANDA ANDA204446 07/08/2015 OOXYCYCLINE Journal of Administration Product Information Product Information Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Active Ingredient/Active Moiety Active Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNNI: N120000130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE DOXYCYCLINE Ts mo			E; Type 0: Not a Combination	01/31/20	40			
Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204446 07/08/2015 Marketing End Date DOXYCYCLINE 07/08/2015 V V Product Information V V V Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL ORAL V V Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNNI: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE DOXYCYCLINE Ts ma			TLE; Type 0: Not a Combination	01/31/20	40			
Marketing Category ANDA Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204446 07/08/2015 07/08/2015 DOXYCYCLINE doxycycline capsule Item Code (Source) NDC:43386-791 Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL ORAL Item Code (Source) NDC:43386-791 Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg								
Marketing Category ANDA Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204446 07/08/2015 07/08/2015 DOXYCYCLINE doxycycline capsule Item Code (Source) NDC:43386-791 Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL ORAL Item Code (Source) NDC:43386-791 Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg								
Category Citation Date Date ANDA ANDA204446 07/08/2015 Date OOXYCYCLINE DOXYCYCLINE Product Information Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg	Marketing	g Informat	ion					
ANDA ANDA204446 07/08/2015 DOXYCYCLINE doxycycline capsule Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 15 mg				Mar				
doxycycline capsule Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL ORAL NDC:43386-791 Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg	ANDA			07/08/			ace	
doxycycline capsule Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL ORAL NDC:43386-791 Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg		1				1		
doxycycline capsule Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL ORAL NDC:43386-791 Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg								
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL ORAL NDC:43386-791 Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg								
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg	doxycycline ca	ipsule						
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43386-791 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg	Due duet luf							
Route of Administration ORAL Active Ingredient/Active Moiety Basis of Strength Ingredient Name Basis of Strength DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg								
Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg	••			Item C	ode (Source)	NDC:4	3386-791	
Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg	Route of Adm	ninistration	ORAL					
Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg								
Ingredient Name Basis of Strength Strengt DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg	Active Ingre	edient/Active	Moiety					
DOXYCYCLINE (UNII: N12000U130) (DOXYCYCLINE ANHYDROUS - DOXYCYCLINE 75 mg					Basis of S	trenath	Strength	
			· · · · · · · · · · · · · · · · · · ·					
) (DOXYCYCLINE ANHYDROUS -		DOXYCYCLINE		75 mg	

Inactive Ingredients	
Ingredient Name	Strength
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
GELATIN (UNII: 2G86QN327L)	
SODIUM LAURYL SULFATE (UNII: 368GB5141J)	
FERROSOFERRIC OXIDE (UNII: XM0M87F357)	
FERRIC OXIDE RED (UNII: 1K09F3G675)	
FERRIC OXIDE YELLOW (UNII: EX43802MRT)	
SHELLAC (UNII: 46N107B710)	
POTASSIUM HYDROXIDE (UNII: WZ H3C48M4T)	

Product Characteristics

Color	WHITE (Opaque Body) , BROWN (Opaque Cap)	Score	no score
Shape	CAPSULE	Size	18mm
Flavor		Imprint Code	NL791;75mg
Contains			

Packaging

\$	tem Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:43386-791- 01	100 in 1 BOTTLE; Type 0: Not a Combination Product	07/08/2015	
2	NDC:43386-791- 11	50 in 1 BOTTLE; Type 0: Not a Combination Product	01/31/2040	
з	NDC:43386-791- 10	1000 in 1 BOTTLE; Type 0: Not a Combination Product	01/31/2040	

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204446 07/08/2015 07/08/2015

doxycycline capsule					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Co	de (Source)	NDC:4	3386-792
Route of Administration	ORAL	item co			5500 / 52
A athree larger alie att/A athree	Malaka				
Active Ingredient/Active	•				
Ing	redient Name		Basis of Str	ength	Strengt
DOXYCYCLINE (UNII: N12000U13	30) (DOXYCYCLINE ANHYDROUS -		DOXYCYCLINE		100 mg
UNII:334895S862)			ANHYDROUS		200
UNII:3348955862)			ANHYDROUS		200 mg
			ANHYDROUS		200
	Ingredient Name		ANHYDROUS	S	trength
Inactive Ingredients	-		ANHYDROUS	S	
Inactive Ingredients	(BU4)		ANHYDROUS	S	
Inactive Ingredients SILICON DIOXIDE (UNII: ETJ7Z6)	KBU4) 0097M6I30)		ANHYDROUS	S	
Inactive Ingredients SILICON DIOXIDE (UNII: ETJ7Z6) MAGNESIUM STEARATE (UNII: 7 CELLULOSE, MICROCRYSTALLI	KBU4) 0097M6I30))	ANHYDROUS	S	
Inactive Ingredients SILICON DIOXIDE (UNII: ETJ7Z6) MAGNESIUM STEARATE (UNII: 7 CELLULOSE, MICROCRYSTALLI SODIUM STARCH GLYCOLATE	(BU4) 0097M6I30) INE (UNII: OP1R32D61U) TYPE A POTATO (UNII: 5856J3G2A2)	ANHYDROUS	S	
Inactive Ingredients SILICON DIOXIDE (UNII: ETJ7Z6) MAGNESIUM STEARATE (UNII: 7 CELLULOSE, MICROCRYSTALLI SODIUM STARCH GLYCOLATE FERROSOFERRIC OXIDE (UNII: 3	(BU4) 10097M6I30) INE (UNII: OP1R32D61U) TYPE A POTATO (UNII: 5856J3G2A2 XM0M87F357))	ANHYDROUS	S	
Inactive Ingredients SILICON DIOXIDE (UNII: ETJ7Z6) MAGNESIUM STEARATE (UNII: 7 CELLULOSE, MICROCRYSTALLI SODIUM STARCH GLYCOLATE FERROSOFERRIC OXIDE (UNII: 1 FERRIC OXIDE RED (UNII: 1K09F	(BU4) (0097M6I30) INE (UNII: OP1R32D61U) TYPE A POTATO (UNII: 5856J3G2A2 (M0M87F357) 3G675))	ANHYDROUS	S	
Inactive Ingredients SILICON DIOXIDE (UNII: ETJ7Z6) MAGNESIUM STEARATE (UNII: 7 CELLULOSE, MICROCRYSTALL SODIUM STARCH GLYCOLATE FERROSOFERRIC OXIDE (UNII: 3 FERRIC OXIDE RED (UNII: 1K09F FERRIC OXIDE YELLOW (UNII: 1	(BU4) (0097M6I30) (NE (UNII: OP1R32D61U) TYPE A POTATO (UNII: 5856J3G2A2 (MOM87F357) 3G675) (X43802MRT))	ANHYDROUS	S	
Inactive Ingredients SILICON DIOXIDE (UNII: ETJ7Z6) MAGNESIUM STEARATE (UNII: 7 CELLULOSE, MICROCRYSTALL	KBU4) (0097M6I30) (NE (UNII: OP1R32D61U) TYPE A POTATO (UNII: 5856J3G2A2 KMOM87F357) 3G675) (X43802MRT) LOQY))	ANHYDROUS	S	

GE	ELATIN (UNII: 20	686QN327L)						
sc	DDIUM LAURYL	SULFATE (UNII: 368GB5141J)						
SHELLAC (UNII: 46N107B710)								
POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)								
P	roduct Chai	racteristics						
		LLOW (Opaque Body) , BROWN (Opaque Cap)		Score	no score			
sł	nape CA	PSULE		Size	19mm			
Fİ	avor			Imprint Code	NL792;100mg			
С	ontains							
	ackaging Item Code	Package Description	Ma	arketing Start Date	Marketing End Date			
#	Item Code	Package Description - 250 in 1 BOTTLE; Type 0: Not a Combination Product						
# 1	Item Code NDC:43386-792 02	- 250 in 1 BOTTLE; Type 0: Not a Combination	07/0	Date				
# 1 2	Item Code NDC:43386-792 02 NDC:43386-792 11	 250 in 1 BOTTLE; Type 0: Not a Combination Product 50 in 1 BOTTLE; Type 0: Not a Combination 	07/0	Date 3/2015				
#	Item Code NDC:43386-792 02 NDC:43386-792 11 NDC:43386-792	 250 in 1 BOTTLE; Type 0: Not a Combination Product 50 in 1 BOTTLE; Type 0: Not a Combination Product 1000 in 1 BOTTLE; Type 0: Not a Combination 	07/0	Date 3/2015 1/2040				
# 1 2 3	Item Code NDC:43386-792 02 NDC:43386-792 11 NDC:43386-792 10	 250 in 1 BOTTLE; Type 0: Not a Combination Product 50 in 1 BOTTLE; Type 0: Not a Combination Product 1000 in 1 BOTTLE; Type 0: Not a Combination Product 	07/0	Date 3/2015 1/2040				
# 1 2 3	Item Code NDC:43386-792 02 NDC:43386-792 11 NDC:43386-792 10	 250 in 1 BOTTLE; Type 0: Not a Combination Product 50 in 1 BOTTLE; Type 0: Not a Combination Product 1000 in 1 BOTTLE; Type 0: Not a Combination Product 	07/03	Date 3/2015 1/2040 1/2040	Date			
¥ L 2	Item Code NDC:43386-792 02 NDC:43386-792 11 NDC:43386-792 10	 250 in 1 BOTTLE; Type 0: Not a Combination Product 50 in 1 BOTTLE; Type 0: Not a Combination Product 1000 in 1 BOTTLE; Type 0: Not a Combination Product 	07/03	Date 3/2015 1/2040				

Labeler - Lupin Pharmaceuticals,Inc. (089153071)

ANDA204446

Registrant - Novel Laboratories, Inc. (793518643)

Establishm	tablishment				
Name	Address	ID/FEI	Business Operations		
Novel Laboratories, Inc.		793518643	ANALYSIS(43386-790, 43386-791, 43386-792) , MANUFACTURE(43386-790, 43386-791, 43386-792)		

07/08/2015

Revised: 1/2024

ANDA

Lupin Pharmaceuticals,Inc.